Compare GROV & XGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GROV | XGN |
|---|---|---|
| Founded | 2016 | 2002 |
| Country | United States | United States |
| Employees | 415 | N/A |
| Industry | Package Goods/Cosmetics | Medical Specialities |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 58.4M | 64.5M |
| IPO Year | N/A | 2014 |
| Metric | GROV | XGN |
|---|---|---|
| Price | $1.30 | $3.07 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 7 |
| Target Price | $1.60 | ★ $9.14 |
| AVG Volume (30 Days) | 91.5K | ★ 278.3K |
| Earning Date | 05-13-2026 | 05-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $8.06 |
| Revenue Next Year | $6.81 | $12.93 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.02 | $2.59 |
| 52 Week High | $1.60 | $12.23 |
| Indicator | GROV | XGN |
|---|---|---|
| Relative Strength Index (RSI) | 44.71 | 46.86 |
| Support Level | $1.19 | N/A |
| Resistance Level | $1.35 | $3.79 |
| Average True Range (ATR) | 0.07 | 0.21 |
| MACD | -0.00 | 0.05 |
| Stochastic Oscillator | 29.17 | 67.14 |
Grove Collaborative Holdings Inc is engaged in providing consumer products. It offers Cleaning accessories, Home and Pantry, Personal care products, Pets supplements and Other products. It is a sustainability oriented consumer products generator. It use connection with consumers to create and curate authentic, disruptive brands and products. Company builds natural products that perform as well as, many consumer packaged goods (CPG) brands (both conventional and natural), while being healthier for consumers and the planet.
Exagen Inc is a medical technology company focused on the design, development and commercialization of diagnostic testing products under its AVISE brand. These products are used for the differential diagnosis, prognosis, and monitoring of rheumatic, autoimmune, and related diseases, including systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA). The company operates in one operating segment. The majority of the company's revenue is derived from sales of its testing products.